Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Mesothelioma: HELP
Articles by Takeharu Yamanaka
Based on 4 articles published since 2008
||||

Between 2008 and 2019, Takeharu Yamanaka wrote the following 4 articles about Mesothelioma.
 
+ Citations + Abstracts
1 Clinical Trial Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial). 2016

Hasegawa, Seiki / Okada, Morihito / Tanaka, Fumihiro / Yamanaka, Takeharu / Soejima, Toshinori / Kamikonya, Norihiko / Tsujimura, Tohru / Fukuoka, Kazuya / Yokoi, Kohei / Nakano, Takashi. ·Department of Thoracic Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan. hasegawa@hyo-med.ac.jp. · Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan. · Department of Surgery, University of Occupational and Environmental Health, Kitakyusyu, Japan. · Department of Biostatistics, Yokohama City University, Yokohama, Japan. · Department of Radiation Oncology, Hyogo Cancer Center, Akashi, Japan. · Department of Radiation Oncology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan. · Department of Pathology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan. · Department of Medical Oncology, Sakai Hospital, Kinki University Faculty of Medicine, Osaka, Japan. · Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. · Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan. ·Int J Clin Oncol · Pubmed #26577445.

ABSTRACT: PURPOSE: We conducted a prospective multi-institutional study to determine the feasibility of trimodality therapy (TMT) comprising induction chemotherapy followed by extrapleural pneumonectomy (EPP) and radiation therapy in Japanese patients with malignant pleural mesothelioma (MPM). METHODS: Major eligibility criteria were histologically confirmed diagnosis of MPM, including clinical subtypes T0-3, N0-2, M0 disease; no prior treatment for the disease; age 20-75 years; Eastern Cooperative Oncology Group performance status 0 or 1; predicted postoperative forced expiratory volume >1000 ml in 1 s; written informed consent. Treatment methods comprised induction chemotherapy using pemetrexed (500 mg/m(2)) plus cisplatin (60 mg/m(2)) for three cycles, followed by EPP and postoperative hemithoracic radiation therapy (54 Gy). Primary endpoints were macroscopic complete resection (MCR) rate for EPP and treatment-related mortality for TMT. RESULTS: Forty-two eligible patients were enrolled: median age 64.5 (range 43-74) years; M:F = 39:3, clinical stage I:II:III = 14:13:15; histological type epithelioid were sarcomatoid; biphasic; others = 28:1:9:4. Of 42 patients, 30 completed EPP with MCR and 17 completed TMT. The trial met the primary endpoints, with an MCR rate of 71 % (30/42) and treatment-related mortality of 9.5 % (4/42). Overall median survival time and 2-year survival rate for 42 registered patients were 19.9 months and 42.9 %, respectively. Two-year relapse-free survival rate of 30 patients who completed EPP with MCR was 37.0 %. CONCLUSION: This phase II study met the predefined primary endpoints, but its risk/benefit ratio was not satisfactory.

2 Clinical Trial A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma. 2013

Shimokawa, Mototsugu / Hasegawa, Seiki / Fukuoka, Kazuya / Okada, Morihito / Yokoi, Kohei / Tanaka, Fumihiro / Yamanaka, Takeharu / Daimon, Takashi / Nakano, Takashi. ·Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan. shimokawa.m@nk-cc.go.jp ·Jpn J Clin Oncol · Pubmed #23509402.

ABSTRACT: A prospective multi-institutional study has been initiated in Japan to evaluate the feasibility of induction chemotherapy using pemetrexed plus cisplatin, followed by pleurectomy/decortication aimed at macroscopic complete resection in patients with resectable malignant pleural mesothelioma. The study was initiated on September 2012, for which 24 patients will be recruited over a period of 2 years. The primary endpoint is the macroscopic complete resection rate, regardless of the surgical technique employed (i.e. pleurectomy/decortication or extrapleural pneumonectomy). The secondary endpoints are the pleurectomy/decortication rate, macroscopic complete resection rate by pleurectomy/decortication, pulmonary function at 3 months after surgery, adverse events, treatment-related mortality, response rate to chemotherapy and 3-year overall survival rate.

3 Clinical Trial [Current status and future direction of Japan's clinical trial for malignant pleural mesothelioma]. 2011

Hasegawa, Seiki / Tanaka, Fumihiro / Okada, Morihito / Yamanaka, Takeharu / Kamikonya, Norihiko / Soejima, Toshinori / Tsujimura, Tohru / Fukuoka, Kazuya / Nakano, Takashi. ·Department of Thoracic Surgery, Hyogo College of Medicine, Mukogawa-cho, Nishinomiya, Japan. hasegawa@hyo-med.ac.jp ·Nihon Eiseigaku Zasshi · Pubmed #21701087.

ABSTRACT: The feasibility and efficacy of trimodality therapy for malignant pleural mesothelioma (MPM) are still controversial mainly due to the lack of clinical evidence. Although three major clinical trials on this therapy have been recently reported from North America and Europe, it remains unclear whether results in Caucasian populations may be directly applicable to Asian populations. In this context, as a project of the "Comprehensive approach on asbestos-related diseases" supported by the "Special Coordination Fund for Promoting Science and Technology of MEXT, Japan", a prospective multi-institutional study has been planned to evaluate the feasibility of induction chemotherapy using pemetrexed plus cisplatin, followed by extrapleural pneumonectomy (EPP) and postoperative hemithoracic radiation in patients with resectable MPM. Primary endpoints are macroscopic complete resection rate by EPP and treatment-related mortality for trimodality therapy. The study was initiated in May 2008 and patient enrollment was finished in November 2010.

4 Clinical Trial A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma. 2009

Yamanaka, Takeharu / Tanaka, Fumihiro / Hasegawa, Seiki / Okada, Morihito / Soejima, Toshinori / Kamikonya, Norihiko / Fukuoka, Kazuya / Nakano, Takashi. ·Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa, Nishinomiya, Hyogo, Japan. ·Jpn J Clin Oncol · Pubmed #19131427.

ABSTRACT: A prospective multi-institutional study has been commenced in Japan to evaluate the feasibility of induction chemotherapy using pemetrexed plus cisplatin, followed by extrapleural pneumonectomy (EPP) and postoperative hemithoracic radiation in patients with resectable malignant pleural mesothelioma. The study was initiated on May 2008 and 40 patients will be recruited over 3 years. Primary endpoints are macroscopic complete resection rate by EPP and treatment-related mortality for trimodality therapy. Secondary endpoints include treatment completion rate, adverse events, response rate by chemotherapy and 2-year overall and relapse-free survival.